8 results about "Galactosamine" patented technology

The application discloses a marine red alga polysaccharide extract and application thereof, and belongs to the technical field of marine organisms and medicines. Gigartina radula The polysaccharide extract is extracted from marine red algae, and the main component is natural galactosamine sulfate, contains galactose and glucose, has a sulfate content of 20-40%, a 3,6-endo ether galactose content of 20-50%, and a viscosity of 80-400 mPa s. The polysaccharide extract contains kappa-carrageenan structural units, iota-carrageenan structural units, mu-carrageenan structural units, nu-carrageenan structural units and lambda-carrageenan structural units, and the proportion of the lambda-carrageenan structural units is 10-50%. The marine red alga polysaccharide extract can be applied to the preparation of medicines or functional skin care products for preventing and / or treating inflammatory and immune-related skin diseases such as atopic dermatitis AD.

The application discloses a marine-derived compound Cpd-8 and application thereof in preparation of a medicine for resisting TNF-induced cell death. Through screening of an extract library of marine-derived sponge symbiotic fungi of a research group, a small-molecule inhibitor with a novel structure is obtained, which can resist TNF-induced cell death, and specifically, the marine-derived sesquiterpene lactone nitrobenzene analogue Cpd-8 and a pharmaceutically acceptable salt thereof. The compound can inhibit TNF-induced cell death and formation of a complex II in a signal pathway, thereby exerting an anti-cell death activity. In-vitro cell experiment results show that the compound of the application can significantly inhibit TNF-induced cell death. In-vivo animal experiment results show that the compound of the application can inhibit TNF-alpha / D-GaIN (D-galactosamine)-induced acute liver injury, and significantly prolong the survival period of mice.

The application belongs to the technical field of biological medicine, and relates to a liver-targeting compound, a conjugate and application. The liver-targeting compound has a structure shown in formula I, T is a targeting group, B is a branch structure, L1 is a connecting group, L2 is a connecting part between the targeting group and the branch structure, and X is selected from integers between 2 and 6. The liver-targeting compound and the conjugate have clear structures, multiple galactose, galactosamine or galactosamine derivative molecules are linked into a three-cluster or four-cluster molecule to form a molecular cluster form, the affinity to ASGPR is obviously higher than the affinity of a single sugar, the drug liver-targeting delivery capacity can be improved, the delivery efficiency is high, and a long-acting inhibitory effect can be maintained; and the synthesis route is clear, and the preparation process is simple.

This invention belongs to the field of biomedical technology, specifically relating to a dihydroporphyrin e6 conjugate and its applications. Using dihydroporphyrin e6 and N-p-toluenesulfonyl ethylenediamine as raw materials, an N-p-toluenesulfonyl ethylenediamine-dihydroporphyrin e6 conjugate is prepared by condensation; then, the N-p-toluenesulfonyl ethylenediamine-dihydroporphyrin e6 conjugate is condensed with excess galactosamine hydrochloride to prepare an N-p-toluenesulfonyl ethylenediamine-dihydroporphyrin e6-digalactosamine conjugate. This conjugate exhibits improved water solubility and can target liver cancer cells and the intracellular endoplasmic reticulum, showing potential application value in the field of photodynamic immunotherapy for liver cancer.

The present invention provides a topical skin preparation composition containing a heparin-like substance that has an excellent effect in improving the skin barrier function. [Solution] A topical skin preparation composition containing a heparin-like substance (A) in which the proportion of disaccharide units consisting of C2-sulfated D-glucuronic acid and C4,C6-disulfated N-acetyl-D-galactosamine is 7 to 22 mol%.

This invention provides a filamentous fungus in which wall growth formation is suppressed, and the use of said filamentous fungus. [Solution] Use a filamentous fungus lacking one or more genes selected from the galactosaminogalactan biosynthesis gene group and one or more genes selected from the chitin biosynthesis gene group, or a filamentous fungus in which the expression of one or more genes selected from the galactosaminogalactan biosynthesis gene group and one or more genes selected from the chitin biosynthesis gene group is suppressed.

This invention relates to a method for synthesizing 6-azido-6-deoxy-2-N-acetyl-monosaccharide-nucleoside diphosphate, particularly 6-azido-6-deoxy-2-N-acetyl-D-galactosamine-nucleoside diphosphate or 6-azido-6-deoxy-2-N-acetyl-D-glucosamine-nucleoside diphosphate. The synthetic method according to the invention is characterized by high efficiency and high yield. Another part of the invention concerns the key intermediates of this method.

The present disclosure includes methods of treating 05-associated disease or disorder, such as myasthenia gravis, with a combination that includes an antibody or antigen-binding fragment thereof that binds specifically to C5 and a C5 iRNA which is a glycoconjugate that includes a ligand having terminal N-Acetylgalactosamine (GalNAc) residues and / or N-acetylglucosamine (GIcNAc) residues; or with the C5 iRNA monotherapy.